Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
All content for MyeConversations by Myeloma Australia is the property of Myeloma Australia and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
In this episode we meet Emeritus Professor Doug Joshua. We examine the origins of myeloma and how this orphan disease has made massive segways in the treatment and care of people living with myeloma. Emeritus Professor Doug Joshua also gives us his opinon on what he thinks the future of myeloma may look like.
MyeConversations by Myeloma Australia
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
